Brief Summary

Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in clinical practice. This arrhythmia is responsible for 15% of strokes and more than 30% of strokes on people over 65 years. According to studies, 30 to 40% of isolated atrial fibrillations could be familial. Atrial fibrillation has significant genetic heterogeneity. About 40 genes have been identified as potentially involved. Studies have identified genes common to the risk of atrial fibrillation and stroke. Despite the pathophysiology of atrial fibrillation has been intensively and extensively studied for almost a century, there are still many questions. The pathophysiology is not sufficiently understood to allow finding more effective therapies. It is necessary to identify genetic determinants and thus potentially new pharmacological targets more adapted. The establishment of a biological database will test hypotheses concerning the genetic origin and thromboembolic process of atrial fibrillation and associated stroke.

Trial Health

On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment

1,000

participants targeted

Target at P75+ for all trials

Timeline

85mo left

Started Apr 2018

Longer than P75 for all trials

Geographic Reach

1 country

5 active sites

Status

recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

15 years study duration

Study Progress54%

Apr 2018Apr 2033

First Submitted

Initial submission to the registry

January 31, 2018

Completed

3 months until next milestone

Study Start

First participant enrolled

April 23, 2018

Completed

3 months until next milestone

First Posted

Study publicly available on registry

August 2, 2018

Completed

14.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 23, 2033

Expected

Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 23, 2033

Last Updated

April 17, 2026

Status Verified

April 1, 2026

Enrollment Period

15 years

First QC Date

January 31, 2018

Last Update Submit

April 16, 2026

Conditions

Stroke Atrial Fibrillation

Outcome Measures

Primary Outcomes (3)

Quality of DNA sample
Quality is based on the measure of the purity of DNA with absorbance assay at 260/280nm on a spectrophotometer. For Plasma sample, purity is based on absence of hemolyzed blood by visual observation.
1 day (the day of the storage)
Quality of Plasma sample
Quality is based on the purity of Plasma sample that is based on absence of hemolyzed blood by visual observation.
1 day (the day of the storage)
Quality of preservation of the sample
The quality of preservation of the sample throughout the conservation duration is based on the number of freezing/thawing of each cryotube that will be notified. As weel as any interruption in the freezing process (power failure, freezer failure).
7 years (during all the duration of the collection)